FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP

	OMB APP	ROVAL
	OMB Number:	3235-0287
	Estimated average be	urden
-	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wilson Marc (Last) (First) (Middle) C/O CRINETICS PHARMACEUTICALS, INC.					3. D 01/0	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [CRNX] 3. Date of Earliest Transaction (Month/Day/Year) 01/02/2024								5. Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) CFO				
6055 LUSK BOULEVARD (Street) SAN DIEGO CA 92121				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)			(Zip)		Ru	Rule 10b5-1(c) Transaction Indication										i to		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1)			Benefic	s Form ally (D) o ollowing (I) (In		Direct of Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)						
								Code	v	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			,111341. 4)	
Common Stock 01/02/2				2024	2024		M		10,000	A	\$9.28	106	106,055(1)		D			
Common Stock 01/02/2			2024	2024		S ⁽²⁾		10,000	D	\$35.47	96,055			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Conversion or Exercise Price of Derivative Security		Date,	4. Transactio Code (Inst 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares					
Non- qualified stock option (Right to Buy)	\$9.28	01/02/2024			M			10,000	(4)		05/24/2028	Common Stock	10,000	\$0.00	51,185	5	D	

Explanation of Responses:

- 1. Includes 454 shares acquired under the Issuer's Employee Stock Purchase.
- $2. \ The \ sale \ reported \ in \ this \ Form \ 4 \ was \ effected \ automatically \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan.$
- 3. The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of \$35.47 per share. The range of sales prices on the transaction date was \$34.41 to \$36.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- 4. 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Remarks:

/s/ Marc Wilson

01/04/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.